OIRA Conclusion of EO 12866 Regulatory Review
RIN: 0910-ZB46 View EO 12866 Meetings | Received Date: 01/24/2023 |
Title: Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Draft Guidance for Industry | |
Agency/Subagency: HHS / FDA | Stage: Notice |
Concluded Action: Consistent with Change | Concluded Date: 02/01/2023 |
Section 3(f)(1) Significant *: No | |
Legal Deadline: None | Economically Significant **: No |
Publication Date: | Unfunded Mandates: No |
Major: No | Related To Homeland Security: No |
Regulatory Flexibility Analysis Required: Undetermined | Small Entities Affected: |
Federalism Implications: No | Affordable Care Act [Pub. L. 111-148 & 111-152]: No |
International Impacts: No | Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No |
Pandemic Response: No | |
|